SCODiA Report by MLBI Lab

Single-Cell Transcriptomic and Genomic Landscape of Lung Cancer Progression: Elucidating Cellular Dynamics, Immune Evasion, and Therapeutic Vulnerabilities

This comprehensive single-cell analysis maps the molecular and cellular dynamics of lung cancer progression from normal to early and advanced tumor stages. Key findings include widespread genomic instability and aneuploidy in tumor-origin Lung Epithelial cells, coupled with their active proliferation driven by dysregulated cell cycle genes (e.g., MCM7, E2F4). The tumor microenvironment undergoes significant remodeling, characterized by decreased anti-tumor NK cell populations, increased immunosuppressive regulatory T cells (Treg), and a shift towards pro-tumorigenic M2B macrophages. Pathological cell-cell interactions, particularly involving EGFR, TGF-beta, and CD47-SIRPα signaling, establish an immune-evasive and pro-growth niche. Condition-specific surface markers further reveal distinct phenotypes for malignant epithelial cells, tumor-associated macrophages, and fibroblasts, highlighting potential diagnostic and therapeutic vulnerabilities.

Contents

  1. Dataset overview
  2. UMAP Visualization of Single-Cell RNA-Seq Data by Condition, Sample, Cell Type, and Ploidy
  3. Major Cell Type Score and Ploidy Distribution on UMAP
  4. Celltype Subtype Marker Expression Analysis for Annotation Validation
  5. Tumor-Origin Lung Epithelial Cell CNV Analysis: Patterns and Clinical Significance
  6. UMAP Visualization of CNV Patterns across Cell Types, Ploidy, and Conditions in Lung Tissue
  7. Minor Cell Type Population Analysis Across Lung Conditions
  8. T Cell Subtype Population Dynamics Across Lung Tissue Conditions
  9. T cell Subset Population Analysis Across Lung Conditions
  10. Macrophage Subset Population Analysis Across Lung Cancer Conditions
  11. Macrophage Subset Population Shifts Across Lung Cancer Progression
  12. Ploidy Status of Lung Epithelial Cells Across Normal, Early, and Advanced Lung Cancer Conditions
  13. Cell-Cell Interaction Patterns in Lung Cancer Microenvironment
  14. Immune Checkpoint and Cell Cycle Pathway Cell-Cell Interactions Across Lung Cancer Progression
  15. Condition-Specific Cell-Cell Interaction Patterns in Lung Cancer
  16. Lung Epithelial Cell Condition-Specific Surfaceome Markers
  17. Macrophage Condition-Specific Surfaceome Markers in Lung Tissue
  18. Fibroblast Condition-Specific Surfaceome Markers in Normal and Early-Stage Lung Tumors
  19. CD4+ T Cell Condition-Specific Surfaceome Markers in Lung Cancer
  20. Dysregulation of Cell Cycle Pathway Genes in Lung Epithelial Cells Across Tumor Progression
  21. Lung Epithelial Cell Gene Ontology (GSA) Analysis: Condition-Specific Pathway Enrichment
  22. Gene Set Enrichment Analysis (GSEA) Across Cell Types and Conditions in Lung Tissue
  23. Discussion
  24. Query List

0. Dataset overview

Dataset Summary

Precomputed Analyses: The dataset includes precomputed results for

1. UMAP Visualization of Single-Cell RNA-Seq Data by Condition, Sample, Cell Type, and Ploidy

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, a dimensionality reduction technique used to visualize the high-dimensional single-cell RNA sequencing data in a 2D space. The UMAPs are colored by various metadata attributes, including condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset. This comprehensive visualization allows for an assessment of dataset structure, cell type clustering quality, sample integration, and the distribution of key biological features like tumor condition and ploidy status.

Visual Summary

Condition UMAP

The UMAP colored by condition (Normal, Tumor(adv), Tumor(early)) reveals distinct segregation between normal and tumor cells. Normal cells (dark red) form a well-defined set of clusters primarily located on the left and upper-left regions of the UMAP. Tumor cells, both advanced (light yellow) and early (dark blue), largely occupy the central and right portions of the embedding. While there's a clear separation from normal cells, Tumor(early) and Tumor(adv) cells show substantial intermixing, suggesting a continuum of transcriptional states during tumor progression or shared cellular adaptations within the tumor microenvironment.

Sample UMAP

The sample UMAP displays a remarkable intermixing of cells from different samples across the entire embedding. This indicates successful integration of data, effectively minimizing strong sample-specific batch effects and allowing for a robust biological interpretation across diverse patient samples. While some small, peripheral clusters might be enriched for specific samples, the overall distribution suggests that the biological signals are dominant over technical variations.

Cell_type_major UMAP

The celltype_major UMAP shows excellent separation of distinct cell lineages. Large, well-defined clusters are observed for:

The clear boundaries between these major cell types affirm the robustness of the initial cell type annotation.

Cell_type_minor UMAP

Further refinement of the major cell types is evident in the celltype_minor UMAP:

This level of detail indicates that the annotation captures expected biological heterogeneity and provides confidence in differentiating closely related cell populations.

Ploidy_dec UMAP

The ploidy_dec UMAP highlights the distribution of aneuploid and diploid cells. Aneuploid cells (dark red) are predominantly concentrated in specific, well-defined clusters, mainly in the upper-mid and left-mid regions. Diploid cells (light yellow) are broadly distributed across the majority of the UMAP, reflecting the abundance of normal and non-malignant cells. The distinct localization of aneuploid cells suggests they correspond to specific cellular populations.

Celltype_subset UMAP

The celltype_subset UMAP provides the highest resolution of cell type identities, revealing intricate sub-populations:

This granularity further validates the comprehensive and high-resolution nature of the single-cell annotations.

Biological Interpretation

  1. Tumor Microenvironment Heterogeneity: The UMAPs clearly illustrate the profound transcriptomic differences between normal and tumor lung tissues. The spatial separation of normal cells from tumor cells in the condition UMAP suggests distinct underlying biological processes. The substantial overlap between early and advanced tumor stages could imply common adaptive mechanisms or a continuous evolution of the tumor cells and their microenvironment.
  2. Robust Cell Type Identification: The sequential resolution from celltype_major to celltype_minor and celltype_subset UMAPs demonstrates highly effective cell type annotation. The distinct clustering of cell populations at each hierarchical level, without excessive mixing, provides strong confidence in the assigned cell identities. This robust annotation is crucial for downstream analyses, ensuring that differential gene expression and pathway analyses are performed on biologically meaningful and homogeneous cell populations.
  3. Malignant Cell Identification through Ploidy: The localized distribution of Aneuploid cells in specific UMAP regions, particularly when compared with the celltype_major UMAP, strongly suggests these correspond to malignant cells. Given that Lung Epithelial cell is designated as the 'Tumor origin celltype', it is highly probable that these aneuploid clusters represent the transformed epithelial cells, which are a hallmark of lung cancer [1]. These aneuploid populations likely overlap with the Lung Epithelial cell clusters, especially those enriched in the Tumor(adv) and Tumor(early) conditions, providing a crucial biological marker for tumor cells within the dataset.
  4. Complex Immune Landscape: The detailed celltype_subset UMAP reveals the high diversity of immune cells within the lung tissue. The presence of various T cell subsets (cytotoxic, regulatory, helper T cells) and distinct macrophage polarization states (M1, M2 subtypes) highlights the complex immune responses active in the lung, likely shaped by the tumor microenvironment. Understanding the precise distribution and activation states of these immune cells is critical for deciphering anti-tumor immunity and immune evasion mechanisms.

Annotation Notes

---

References:

  1. Aneuploidy in Cancer: For general information on aneuploidy as a hallmark of cancer. PubMed search: "aneuploidy cancer" OR "aneuploidy tumor"

2. Major Cell Type Score and Ploidy Distribution on UMAP

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell types inferred by HiCAT scores and their corresponding spatial relationships on a UMAP embedding. Additionally, it overlays ploidy status (Aneuploid/Diploid) and the pre-existing celltype_major annotations onto the same UMAP space. This allows for an assessment of cell type annotation quality and the identification of potentially malignant cell populations based on aneuploidy.

Visual Summary

The UMAP embedding reveals a complex cellular landscape, where different major cell types are largely organized into distinct clusters.

Cell Type Score Distribution:

Ploidy Status (ploidy_dec):

Celltype Annotation (celltype_major):

Biological Interpretation

The visualizations confirm a robust and well-separated clustering of major cell types within the UMAP embedding. The high correlation between the HiCAT_major_score for each cell type and the pre-annotated celltype_major clusters indicates high confidence in the cell type assignments generated by the scoring method. This is critical for downstream analyses, as accurate cell type identification is foundational.

A key observation pertains to the Lung Epithelial cell population. Given that "Lung Epithelial cell" is specified as the "Tumor origin celltype" in the data context, its co-localization with Aneuploid cells is highly significant. This strong overlap suggests that the aneuploid cell populations predominantly represent the malignant tumor cells derived from lung epithelial lineage. The presence of aneuploidy is a hallmark of cancer, reflecting genomic instability and often correlating with tumor progression and severity [1].

The observation that immune cells (T cells, B cells, Myeloid cells, Mast cells) and stromal cells (Fibroblasts, Smooth muscle cells, Endothelial cells) are largely Diploid is consistent with their expected non-malignant roles within the tumor microenvironment or normal tissue. While immune cells can exhibit functional changes in cancer, their genomic integrity typically remains diploid, unless they are undergoing specific transformation events (which are rare for typical tumor-infiltrating lymphocytes or myeloid cells).

Annotation Notes

The strong concordance between the HiCAT_major_score plots and the celltype_major reference plot confirms the quality and consistency of the major cell type annotations across the dataset. The scoring method effectively delineates distinct cell populations, reinforcing the confidence in the cell type labels used for subsequent analyses. The minor populations labeled as 'unassigned' in the celltype_major plot do not show clear high scores for any specific major cell type, which is expected for cells that couldn't be definitively classified into one of the predefined major types.

References

  1. Aneuploidy in Cancer: Search PubMed for "aneuploidy cancer hallmark" for extensive literature. Example: https://pubmed.ncbi.nlm.nih.gov/?term=aneuploidy+cancer+hallmark

3. Celltype Subtype Marker Expression Analysis for Annotation Validation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of key marker genes across different celltype_subset populations identified in the single-cell RNA-seq data from human lung tissue. The primary goal is to visualize cell type-specific gene expression patterns to validate the granular cell subtype annotations and assess their distinct molecular identities. Each dot's size represents the fraction of cells within a group expressing a particular gene, while its color intensity indicates the mean expression level of that gene within the group. The red boxes highlight marker genes that are particularly enriched and specific to a given cell subtype, aiding in the assessment of annotation quality.

Visual Summary

The dot plot effectively visualizes the distinct expression profiles of marker genes across 38 identified celltype_subset populations. A clear diagonal pattern of enriched gene expression is observed, where specific genes are highly expressed and prevalent in their corresponding cell subtypes, confirming the specificity of these markers.

Biological Interpretation

The marker expression patterns observed in this dot plot strongly support the robust and granular annotation of celltype_subset populations within the human lung tissue. Each major cell lineage, such as epithelial cells, immune cells, stromal cells, and endothelial cells, is further subdivided into specific functional or developmental subtypes, and their molecular identities are confirmed by canonical marker gene expression.

Immune Cell Lineage Confirmation:

Overall, the observed marker expression patterns align very well with established biological knowledge for human lung cell types, confirming the high quality and accuracy of the celltype_subset annotations.

Annotation Notes

This analysis provides strong evidence for the validity and specificity of the celltype_subset annotations. The distinct and expected expression of canonical marker genes across almost all identified cell subtypes confirms that these annotations accurately represent unique cell populations with characteristic molecular profiles. This robust annotation is critical for downstream analyses, ensuring that differential expression, pathway analysis, and cell-cell interaction studies are performed on accurately defined cell populations. The clear segregation of cell identities, even at a granular level (e.g., different T helper subsets, macrophage polarization states), highlights the success of the annotation strategy.

---

References:

  1. HOPX in Alveolar Type 1 Cells:

PubMed search: HOPX alveolar type 1

  1. SFTPC, SFTPB, NAPSA in Alveolar Type 2 Cells:

GeneCards: SFTPC

GeneCards: SFTPB

GeneCards: NAPSA

  1. Airway Epithelial Cell Markers:

PubMed search: KRT5 FOXJ1 MUC5B SCGB1A1 lung epithelium

  1. Dendritic Cell Markers:

PubMed search: CD1A CLEC9A LILRA4 IRF7 dendritic cell lung

  1. Mast Cell Markers:

GeneCards: KIT

GeneCards: TPSAB1

  1. NK Cell Markers:

GeneCards: KLRD1

GeneCards: GZMB

  1. Plasma Cell Markers:

GeneCards: JCHAIN

GeneCards: XBP1

  1. T Cell Subset Markers:

PubMed search: CD8A FOXP3 STAT4 RORC GATA3 T cell lung

  1. Fibroblast Markers:

PubMed search: COL1A1 DCN lung fibroblast

  1. Endothelial Cell Markers:

GeneCards: PLVAP

GeneCards: PECAM1

4. Tumor-Origin Lung Epithelial Cell CNV Analysis: Patterns and Clinical Significance

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) specifically within tumor-origin Lung Epithelial cells from single-cell RNA-seq data. The goal is to identify common and unique CNV patterns across different patient samples and conditions (Normal, Tumor(early), Tumor(adv)) and to summarize regions with significant amplifications. The results include a CNV heatmap displaying log2(CNR) values across genomic spots for each sample group, alongside a summary heatmap and bar plot highlighting the frequency of amplified cytogenetic bands.

Visual Summary

The visualization consists of two main parts: a CNV heatmap and a summary of significantly amplified regions.

CNV Heatmap (log2(CNR))

Summary of Significantly Amplified Regions

Biological Interpretation

The CNV analysis on Lung Epithelial cells provides crucial insights into the genomic instability and driver alterations in lung cancer.

Clinical or Translational Implications

5. UMAP Visualization of CNV Patterns across Cell Types, Ploidy, and Conditions in Lung Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of UMAP (Uniform Manifold Approximation and Projection) plots derived from single-cell RNA-seq data, specifically leveraging estimated Copy Number Variation (CNV) patterns (obsm['X_cnv']) for embedding. These UMAPs visualize the cellular landscape based on CNV similarity, with cells colored by their major cell type, minor cell type, ploidy status, disease condition, and individual sample origin. The primary objective is to investigate how CNV patterns stratify different cell populations and to understand their distribution across various biological and clinical annotations within the lung tissue dataset.

Visual Summary

The UMAP visualizations reveal a clear separation of cells into distinct regions based on their underlying CNV profiles.

celltype_major:

celltype_minor:

ploidy_dec:

condition:

sample:

Biological Interpretation

The UMAPs based on CNV patterns provide a powerful visual segregation of cell populations, primarily distinguishing between likely malignant cells and the non-malignant tumor microenvironment or normal tissue.

  1. Clear Distinction of Malignant Cells: The most striking observation is the clear separation of "Aneuploid" cells into distinct clusters, predominantly composed of "Lung Epithelial cells" (Alveolar and Airway Epithelial cells). Given that Lung Epithelial cells are the tumor origin celltype in this dataset, this strongly suggests that these aneuploid epithelial cells represent the malignant cancer cell population. Malignant transformation is frequently accompanied by widespread chromosomal instability, leading to CNVs and altered ploidy, which is effectively captured by this CNV-based embedding. PubMed search: copy number variation cancer progression
  2. Genomic Stability of Tumor Microenvironment and Normal Cells: The vast majority of immune cells (T cells, Myeloid cells, B cells, etc.) and stromal cells (Fibroblasts, Endothelial cells) cluster tightly within the "Diploid" region. This indicates that these cells, whether from normal tissue or infiltrating the tumor, generally maintain a stable, diploid genome, as expected for non-cancerous cells. This observation provides confidence in the CNV estimation and ploidy assignment for segregating tumor cells from the host microenvironment.
  3. Disease Progression and CNV Profiles: Both "Tumor(early)" and "Tumor(adv)" conditions show enrichment in the aneuploid clusters. This implies that CNVs are present early in tumor development and persist or evolve as the disease progresses to an advanced stage. The overlapping nature of early and advanced tumor cells in the aneuploid space suggests that while CNV burden distinguishes tumor cells from normal, the specific patterns might be complex and heterogeneous across different stages or individual tumors.
  4. Sample Heterogeneity: The sample plot highlights inter-patient variability in CNV profiles within the aneuploid compartment. While all tumor samples contribute to the aneuploid clusters, the specific distribution patterns can vary, which might reflect distinct tumor subclones or varying degrees of genomic instability across patients. The presence of some "normal" samples (LUNG_N31, LUNG_N34) contributing to aneuploid regions could indicate early neoplastic changes, contamination, or samples taken from adjacent but affected tissue.

Annotation Notes

The strong concordance between celltype_major/celltype_minor annotations, ploidy_dec inference, and condition labels within the CNV-derived UMAP embedding provides robust validation for the quality of these annotations. The distinct clustering of aneuploid, epithelial cells from tumor conditions, separate from diploid immune and stromal cells from normal and tumor conditions, confirms the biological accuracy of the CNV estimates and their utility in distinguishing cell states. The 'Unclear' ploidy cells are a minor population and do not significantly interfere with the overall interpretation.

6. Minor Cell Type Population Analysis Across Lung Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of minor cell types across individual samples from normal lung tissue, early-stage lung tumors (Tumor(early)), and advanced-stage lung tumors (Tumor(adv)). The purpose is to identify shifts in cellular composition associated with lung tumorigenesis and progression.

Visual Summary

The stacked bar plots display the percentage of each minor cell type within each sample, grouped by condition.

Biological Interpretation

The observed shifts in minor cell type populations provide critical insights into the lung tumor microenvironment (TME) dynamics.

Immune Landscape Alterations

Clinical or Translational Implications

---

References:

  1. Tumor-associated macrophages: Olingy CE, Dinh HQ, Clements VK, et al. The Oncotarget of M2 Macrophages: From Cancer to Novel Therapies. *Front Immunol*. 2019;10:1107. PubMed Search Link
  2. Role of macrophages in TME: Mantovani A, Marchesi F, Malesci A, et al. Tumor-associated macrophages as a double-edged sword in cancer progression. *Nat Rev Clin Oncol*. 2017;14(12):731-744. PubMed Search Link
  3. Immune cells in TME and immunotherapy: Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumors with immunotherapy. *Nat Rev Drug Discov*. 2020;19(11):765-781. PubMed Search Link

7. T Cell Subtype Population Dynamics Across Lung Tissue Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the proportional distribution of various T cell subsets, including NK cells and Innate Lymphoid Cells (ILCs), across individual samples from Normal, early-stage Tumor (Tumor(early)), and advanced-stage Tumor (Tumor(adv)) lung tissues. The plot focuses on the celltype_major 'T cell' and further subdivides it into celltype_subset populations. This visualization helps to identify shifts in the immune landscape during lung tumor progression.

Visual Summary

The stacked bar plot shows the relative abundance of T cell subsets per sample, grouped by condition (Normal, Tumor(adv), Tumor(early)).

Biological Interpretation

The observed shifts in T cell subset populations provide critical insights into the immune microenvironment in lung cancer progression.

Clinical or Translational Implications

These findings have several potential clinical and translational implications for lung cancer:

8. T cell Subset Population Analysis Across Lung Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of various T cell and NK cell subsets across different lung tissue conditions: early-stage tumor (Tumor(early)), normal tissue (Normal), and advanced-stage tumor (Tumor(adv)). The goal is to identify statistically significant shifts in the immune cell composition that may be associated with tumor initiation and progression in the lung, based on single-cell RNA sequencing data.

Visual Summary

The box plots display the proportion of eight distinct immune cell subsets within the total T cell population across the three conditions. Statistically significant differences (p < 0.1) are highlighted by p-values connecting specific group comparisons.

Biological Interpretation

The observed shifts in immune cell proportions reveal dynamic changes in the lung tumor microenvironment (TME) as cancer develops and progresses.

  1. Early Tumor Immune Dysregulation: Several T helper subsets (Tfh, Th22, Th17, Th2) and immunosuppressive Treg cells are significantly elevated in early-stage tumors compared to normal lung tissue. This suggests an initial, perhaps dysregulated, immune response to the nascent tumor.
  1. Weakened Anti-Tumor Immunity:
  1. Progression-Associated Shifts:

Clinical or Translational Implications

These findings have several potential clinical implications for lung cancer:

9. Macrophage Subset Population Analysis Across Lung Cancer Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot showing the proportional distribution of different macrophage subsets (M1, M2A, M2B, M2C, M2D) within the total macrophage compartment across individual samples from Normal, early-stage Tumor (Tumor(early)), and advanced-stage Tumor (Tumor(adv)) lung tissues. The aim is to identify shifts in macrophage polarization that may be associated with tumor development and progression.

Visual Summary

The visualization displays stacked bar plots for each sample, grouped by condition: Normal, Tumor(adv), and Tumor(early). Each bar represents 100% of macrophages in a given sample, with different colors indicating the proportions of M1, M2A, M2B, M2C, and M2D subsets.

Biological Interpretation

Macrophages are highly plastic immune cells that can polarize into various functional states, broadly categorized as M1 (pro-inflammatory, anti-tumorigenic) and M2 (anti-inflammatory, pro-tumorigenic) phenotypes. The observed shifts in macrophage subsets provide critical insights into the tumor microenvironment (TME) dynamics in lung cancer.

  1. Shift from M1 to M2 Dominance in Tumors: The most prominent finding is the general shift from a relatively M1-dominant profile in normal lung tissue towards an increased prevalence of M2-like macrophages (specifically M2A and M2B) in both early and advanced tumor conditions. This observation is consistent with the well-established role of M2 macrophages, often referred to as Tumor-Associated Macrophages (TAMs), in promoting tumor growth, angiogenesis, metastasis, and immune evasion PMID: 29202562.
  2. Role of M1 Macrophages: M1 macrophages are characterized by their ability to kill tumor cells and present antigens, driven by cytokines like IFN-γ and TNF-α. Their relative reduction in tumor samples suggests a compromised anti-tumor immune response within the TME.
  3. Increased M2A and M2B Macrophages:
  1. Implications for Tumor Progression: The consistent increase in M2A and M2B macrophages in both early and advanced tumor stages underscores their early involvement in shaping a pro-tumorigenic microenvironment. This suggests that the tumor actively educates and polarizes macrophages to support its growth, even from early stages. The relatively stable low proportions of M2C and M2D, while important in other contexts, suggest M2A and M2B might be the primary M2-like contributors in this specific lung cancer dataset.

Clinical or Translational Implications

The observed macrophage polarization patterns have significant clinical and translational implications for lung cancer treatment.

  1. Therapeutic Targeting of Macrophage Polarization: The predominance of M2-like macrophages in lung tumors suggests that therapeutic strategies aimed at repolarizing TAMs from an M2 (pro-tumor) to an M1 (anti-tumor) phenotype could be beneficial. This could involve using specific small molecules, antibodies, or immunomodulatory agents PubMed Search: "macrophage repolarization cancer therapy".
  2. Biomarker Potential: The relative proportions of M1 versus M2 macrophage subsets could serve as prognostic biomarkers, predicting disease aggressiveness or response to therapy. Patients with a higher M2/M1 ratio might have a poorer prognosis or be less responsive to certain immunotherapies.
  3. Combination Therapies: Understanding the precise macrophage subset landscape could guide the development of combination therapies. For instance, combining agents that inhibit M2 polarization or function with existing immunotherapotherapies (e.g., checkpoint inhibitors) might enhance anti-tumor immunity and improve patient outcomes PMID: 32371990. Targeting specific M2 subtypes (e.g., M2A or M2B) could lead to more precise interventions.

10. Macrophage Subset Population Shifts Across Lung Cancer Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportions of various macrophage subsets (Mac M2A, M2B, M2C, M2D) across different lung tissue conditions: early-stage tumor (Tumor(early)), normal tissue (Normal), and advanced-stage tumor (Tumor(adv)). The box plots highlight statistically significant differences in the proportions of these macrophage populations, providing insights into their dynamic roles during lung cancer progression.

Visual Summary

The box plots reveal distinct patterns of macrophage subset proportions across the three conditions:

Mac (M2A):

Mac (M2B):

Mac (M2D):

Mac (M2C):

Biological Interpretation

Macrophages are critical components of the tumor microenvironment (TME) and are broadly categorized into M1 (anti-tumorigenic) and M2 (pro-tumorigenic) phenotypes. The subsets analyzed here (M2A, M2B, M2C, M2D) represent distinct M2-like polarization states, each with specific functions in inflammation, immune regulation, and tissue remodeling.

  1. Shift towards Pro-Tumorigenic M2B Macrophages: The most striking finding is the significant and progressive increase of Mac (M2B) populations from normal tissue through early-stage to advanced-stage lung tumors. Mac (M2B) macrophages are known to be induced by immune complexes and Toll-like receptor (TLR) agonists. They typically contribute to pro-inflammatory responses, angiogenesis, and immune suppression within the TME, thereby promoting tumor growth and metastasis [1]. Their enrichment in advanced tumors strongly implicates them in driving disease progression.
  2. Decreased M2A and M2C Macrophages in Advanced Disease: Conversely, Mac (M2A) proportions show a significant decrease with tumor progression, becoming lowest in advanced tumors. M2A macrophages are generally associated with wound healing and tissue repair, often considered a "classically activated" M2 subtype involved in resolving inflammation. Their reduction might suggest a shift away from these reparative functions, potentially favoring more overtly pro-tumorigenic M2 subsets. Mac (M2C) macrophages, typically induced by IL-10 or TGF-β, are known for their strong immune suppressive properties and roles in tissue remodeling. Their observed reduction, especially in advanced tumors, could signify a shift in the immune suppressive landscape or a preferential dominance of other M2 types in later stages of cancer [2].
  3. Dynamic Reprogramming of Macrophages in Lung Cancer: The overall pattern suggests a dynamic reprogramming of macrophage populations in the lung TME. As lung cancer progresses from early to advanced stages, there is a clear shift from relatively higher proportions of M2A (and possibly M2C) towards a dominant presence of M2B macrophages. This re-polarization of macrophages profoundly influences the TME, creating an environment conducive to tumor growth, immune evasion, and metastasis.

Clinical or Translational Implications

The observed shifts in macrophage subset proportions hold significant clinical implications for lung cancer:

---

References:

  1. M2B Macrophages and Tumor Microenvironment:
  1. M2C Macrophages in Cancer:
  1. Macrophage Polarization Therapy in Cancer:

11. Ploidy Status of Lung Epithelial Cells Across Normal, Early, and Advanced Lung Cancer Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, Unclear) of Lung Epithelial cells, identified as the tumor-origin cell type, across different conditions: Normal, Tumor(early), and Tumor(adv). The results are presented as stacked bar plots, showing the percentage of each ploidy category for individual samples within each condition.

Visual Summary

The bar plots display the distribution of ploidy populations within Lung Epithelial cells for each sample, grouped by condition.

Biological Interpretation

The observed ploidy patterns in Lung Epithelial cells provide strong biological insights into lung cancer progression:

Clinical or Translational Implications

---

References:

[1] PubMed search for "hallmarks of cancer aneuploidy": https://pubmed.ncbi.nlm.nih.gov/?term=hallmarks+of+cancer+aneuploidy

[2] PubMed search for "lung cancer aneuploidy prognosis": https://pubmed.ncbi.nlm.nih.gov/?term=lung+cancer+aneuploidy+prognosis

[3] PubMed search for "aneuploidy cancer therapy": https://pubmed.ncbi.nlm.nih.gov/?term=aneuploidy+cancer+therapy

12. Cell-Cell Interaction Patterns in Lung Cancer Microenvironment

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns involving various cell types, including Lung Epithelial cells, Fibroblasts, Macrophages, T cells, B cells, Dendritic cells, Endothelial cells, ILCs, Mast cells, NK cells, Plasma cells, and Smooth muscle cells, across Normal, Tumor (early), and Tumor (advanced) lung tissue conditions. The goal is to identify prominent ligand-receptor interactions that distinguish the tumor microenvironment from normal tissue and to prioritize potential therapeutic targets. The analysis specifically highlights interactions involving both Diploid and Aneuploid Lung Epithelial cells, with aneuploidy serving as a key marker for cancerous cells within the tumor context.

Visual Summary

The dot plots display the most significant (p-value < 0.05, mean expression > 0.01) cell-cell interaction pairs. The x-axis represents specific ligand-receptor pairs, and the y-axis represents interacting cell type pairs. The color intensity of each dot corresponds to the log2(mean) expression of the interaction, with brighter colors (yellow/green) indicating higher interaction strength. The size of the outer circle around each dot indicates the significance of the interaction (-log10(p)), with larger circles representing more significant interactions.

Key Visual Observations:

Biological Interpretation

The observed cell-cell interaction patterns provide critical insights into the biological mechanisms driving lung tumor progression and immune evasion.

  1. Aneuploid Lung Epithelial Cell Centrality: The extensive interactions of Aneuploid Lung Epithelial cells with their microenvironment underscore their active role in recruiting and reprogramming stromal and immune cells. This is a hallmark of cancer, where tumor cells do not act in isolation but actively shape their surroundings to promote growth, survival, and metastasis.
  2. Immune Evasion and Suppression:
  1. Pro-tumorigenic Macrophage Polarization: Macrophages are highly interactive in the tumor microenvironment. Interactions like APOE-TREM2 (especially between Macrophages and Aneuploid Lung Epithelial cells) and SPP1-integrin (involving Macrophages) indicate a shift towards a pro-tumorigenic phenotype (e.g., M2-like tumor-associated macrophages, TAMs). TREM2 activation can lead to immunosuppression, while SPP1 (Osteopontin) promotes inflammation, angiogenesis, and metastasis. PubMed search: APOE TREM2 cancer GeneCards: SPP1
  2. Angiogenesis and Stromal Remodeling:
  1. WNT Signaling: WNT7B-FZD4 interactions, predominantly among Aneuploid Lung Epithelial cells and with Macrophages, suggest active WNT signaling. This pathway is crucial for cell proliferation, differentiation, and development, and its aberrant activation is frequently observed in various cancers, promoting tumor cell survival and growth.

Clinical or Translational Implications

The identified cell-cell interaction patterns offer significant opportunities for therapeutic target prioritization and experimental validation in lung cancer.

  1. Therapeutic Target Prioritization:
  1. Experimental Validation:

13. Immune Checkpoint and Cell Cycle Pathway Cell-Cell Interactions Across Lung Cancer Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) mediated by a selected set of genes associated with immune checkpoint and cell cycle pathways across different lung tissue conditions: Normal, Tumor (early), and Tumor (advanced). The plot_cci_dots tool was used to visualize significant ligand-receptor interactions between various cell types, with dot size representing the statistical significance (-log10(p-value)) and dot color indicating the mean expression level (log2(mean)) of the interacting gene pair. The analysis specifically focuses on how these interactions change with disease progression and the involvement of aneuploid versus diploid cell populations.

Visual Summary

The three dot plots illustrate cell-cell interactions for a curated list of immune checkpoint and cell cycle-related genes across Normal, Tumor (early), and Tumor (advanced) conditions.

Normal Condition:

Tumor (early) Condition:

Tumor (advanced) Condition:

Biological Interpretation

The analysis of cell-cell interactions for immune checkpoint and cell cycle-associated genes reveals dynamic changes in intercellular communication patterns during lung cancer progression, heavily influenced by the emergence of aneuploid tumor cells.

  1. EGFR Signaling Dominance and Progression: In normal lung epithelial cells, baseline autocrine EGFR signaling (AREG_EGFR) is observed. As the tumor develops, particularly with the appearance of aneuploid lung epithelial cells, EGFR signaling intensifies dramatically. This is evidenced by increased strength and significance of multiple EGFR ligand-receptor pairs (AREG_EGFR, BTC_EGFR, EREG_EGFR, HBEGF_EGFR) in early and advanced tumors. This pattern suggests that aberrant activation of the EGFR pathway, driven by both autocrine and paracrine mechanisms (e.g., from macrophages to tumor cells), is a central feature of lung cancer progression, promoting tumor growth and survival. GeneCards: EGFR
  2. Emergence of Immunosuppressive TGF-beta Signaling: TGF-beta signaling becomes increasingly prominent and significant in the tumor microenvironment, especially in advanced stages. The interactions involving TGFB1 with its receptors (TGFBR1, TGFBR2, TGFBR3) and the TGFB1_integrin_avb6_complex are strongly upregulated between aneuploid lung epithelial cells and macrophages, and within the tumor cells themselves. TGF-beta is a known potent immunosuppressive cytokine that promotes tumor growth, metastasis, and fibrosis, while inhibiting anti-tumor immune responses. The integrin_avb6 complex is crucial for activating latent TGF-beta, suggesting an active mechanism for unleashing its pro-tumor effects. PubMed Search: TGFB1 in Lung Cancer
  3. Dynamic Immune Cell Interactions: Interactions involving T cells (T CD8+, T CD4+, NK cells) with other immune cells and tumor cells are consistently present. The IFNG_Type II IFN receptor and LCK_CD8_receptor pathways highlight ongoing immune activity and T-cell function. However, the relatively weak CD86-CD28 co-stimulatory interaction across all conditions might suggest suboptimal T-cell activation, potentially contributing to immune evasion in the tumor microenvironment. While several immune checkpoint genes like PDCD1 (PD-1) and CD274 (PD-L1) were included in the target list, their specific ligand-receptor interactions were not among the most prominent (top 80) in these plots, which could indicate that other immune checkpoint pathways or interactions are more dominant or that their expression levels/interactions are below the specified cutoffs for visualization.
  4. Role of Ploidy Status: The distinction between "Diploid Lung Epi" and "Aneuploid Lung Epi" clearly demonstrates that aneuploid cells drive many of the observed pathological interactions in tumor conditions. This highlights the importance of genomic instability and altered ploidy in shaping the tumor microenvironment and cellular communication networks.

Clinical or Translational Implications

The findings from this cell-cell interaction analysis offer several crucial clinical and translational insights for lung cancer:

  1. Reaffirming EGFR as a Key Therapeutic Target: The sustained and intensified EGFR signaling in aneuploid tumor cells, particularly in advanced disease, strongly supports the continued use and development of EGFR inhibitors. The specific ligands identified (AREG, BTC, EREG, HBEGF) could also serve as biomarkers to stratify patients who might benefit most from EGFR-targeted therapies or to monitor treatment response.
  2. Targeting the TGF-beta Pathway for Immunotherapy and Anti-fibrosis: The robust upregulation of TGF-beta signaling, especially involving the TGFB1_integrin_avb6_complex, presents a compelling rationale for targeting this pathway in advanced lung cancer. TGF-beta inhibitors or agents blocking integrin αvβ6 could reduce immunosuppression, inhibit tumor progression, and alleviate tumor-associated fibrosis, potentially improving responses to existing therapies, including immune checkpoint inhibitors. PubMed Search: TGF-beta inhibitors lung cancer
  3. Addressing Co-stimulation Deficiencies in Immunotherapy: The consistently weak CD86-CD28 interaction suggests a potential deficit in T-cell co-stimulation. Strategies aimed at enhancing co-stimulatory pathways (e.g., agonistic antibodies for CD28 or other co-stimulatory molecules) could be explored in combination with other immunotherapies to boost anti-tumor T-cell responses in lung cancer patients.
  4. Combined Therapeutic Approaches: The co-occurrence of strong pro-oncogenic EGFR signaling and immunosuppressive TGF-beta signaling in advanced tumors suggests that combination therapies targeting both pathways could be more effective than single-agent approaches. For instance, combining EGFR inhibitors with TGF-beta pathway blockers or immune checkpoint inhibitors might synergistically improve patient outcomes.
  5. Biomarker Discovery and Patient Stratification: The specific ligand-receptor pairs identified, such as AREG-EGFR or TGFB1-integrin_avb6_complex, could serve as predictive biomarkers for response to targeted therapies or prognostic indicators of disease aggressiveness, aiding in personalized medicine strategies. Further experimental validation would be crucial to confirm their utility.

14. Condition-Specific Cell-Cell Interaction Patterns in Lung Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies cell-cell interactions (CCIs) involving major immune and stromal cell types that exhibit significant differences across Normal, Tumor (early), and Tumor (advanced) conditions in lung tissue. The CellPhoneDB method was used to infer ligand-receptor interactions, and the results are visualized as a dot plot, where dot color indicates scaled interaction strength and dot size represents statistical significance (-log10(p-value)). This provides insight into how the cellular communication landscape changes during lung tumor progression.

Visual Summary

The dot plot effectively highlights condition-specific patterns of cell-cell interactions.

Biological Interpretation

The observed shifts in cell-cell interactions reflect fundamental changes in the lung microenvironment during tumorigenesis and progression.

  1. Immune Homeostasis in Normal Lung:
  1. Tumor Microenvironment Remodeling:

Clinical or Translational Implications

The differential cell-cell interaction patterns identified have significant clinical and translational implications for lung cancer:

  1. Biomarkers of Progression: The shift from immune-centric to stromal/angiogenic CCIs could serve as a diagnostic or prognostic biomarker panel, distinguishing healthy tissue from early and advanced lung tumors. Specific ligand-receptor pairs, like those involving COL-integrins or VEGF-NRPs, could be measured to assess tumor progression or response to therapy.
  2. Therapeutic Targets:
  1. Understanding Immune Evasion: The observed decrease in immune cell adhesion and activation pathways in tumor conditions suggests mechanisms of immune evasion. Strategies to restore these critical immune interactions could enhance anti-tumor immunity.
  2. Combination Therapies: Given the complex interplay of these pathways, combination therapies that simultaneously target angiogenesis, ECM remodeling, and immunosuppressive signaling may offer more effective treatment strategies than single-agent approaches.

15. Lung Epithelial Cell Condition-Specific Surfaceome Markers

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Lung Epithelial cells from single-cell RNA-seq data. The dot plot visualizes the expression of up to 50 top surfaceome markers per condition (Normal, Tumor(adv), Tumor(early)) across various individual samples. Dot size represents the fraction of cells expressing a given gene within a sample, while dot color intensity indicates the mean expression level. This approach allows for the discovery of surface markers that distinguish different disease states and could serve as diagnostic or therapeutic targets.

Visual Summary

The dot plot effectively stratifies Lung Epithelial cells based on their surfaceome marker expression across Normal, Tumor(adv) (advanced), and Tumor(early) conditions.

Biological Interpretation

The identified surfaceome markers provide critical insights into the biological changes occurring in lung epithelial cells during oncogenesis.

Clinical or Translational Implications

The identified condition-specific surfaceome markers in Lung Epithelial cells hold significant clinical and translational potential.

Diagnostic and Prognostic Biomarkers:

Therapeutic Targets:

16. Macrophage Condition-Specific Surfaceome Markers in Lung Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surface markers for Macrophages found in Lung tissue, comparing Normal samples to early-stage Tumor samples. The dot plot visualizes the expression of these markers across individual patient samples, highlighting differential gene expression patterns that distinguish macrophages in these two distinct microenvironments. Only surfaceome markers were considered, with up to 30 markers selected per condition.

Visual Summary

The dot plot effectively visualizes the expression patterns of macrophage surface markers across various patient samples categorized into 'Normal' and 'Tumor(early)' conditions.

Biological Interpretation

The observed condition-specific surface markers highlight a significant phenotypic remodeling of macrophages in the early tumor microenvironment compared to normal lung tissue.

Clinical or Translational Implications

The identification of condition-specific macrophage surface markers holds significant clinical and translational potential, particularly in the context of early lung cancer.

17. Fibroblast Condition-Specific Surfaceome Markers in Normal and Early-Stage Lung Tumors

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers that are specifically enriched in Fibroblast cells from either normal lung tissue or early-stage lung tumors. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) across individual lung samples, grouped by 'Normal' and 'Tumor(early)' conditions. The goal is to highlight molecular differences in fibroblasts that characterize their state in healthy lung versus the early tumor microenvironment.

Visual Summary

The dot plot clearly segregates Fibroblast surfaceome markers into two distinct groups based on their expression patterns across conditions:

Biological Interpretation

The distinct sets of surfaceome markers underscore a profound phenotypic shift in lung fibroblasts when transitioning from a normal homeostatic state to an early tumor-associated state. This aligns with the concept of cancer-associated fibroblasts (CAFs) being highly reprogrammed cells that actively contribute to the tumor microenvironment.

Clinical or Translational Implications

The identification of highly distinct surfaceome marker panels for normal versus early tumor-associated fibroblasts holds significant clinical and translational potential:

18. CD4+ T Cell Condition-Specific Surfaceome Markers in Lung Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes condition-specific surfaceome markers for CD4+ T cells across Normal, advanced tumor (Tumor(adv)), and early tumor (Tumor(early)) conditions in lung tissue. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for each sample, grouped by condition. The focus is on surfaceome markers, making these candidates highly relevant for cell phenotyping, therapeutic targeting, and cell-cell interaction studies.

Visual Summary

The dot plot clearly delineates distinct patterns of CD4+ T cell surfaceome marker expression across the three conditions:

Biological Interpretation

The observed condition-specific surfaceome profiles of CD4+ T cells reveal distinct functional states across healthy and cancerous lung environments:

Clinical or Translational Implications

These condition-specific surfaceome markers hold significant potential for clinical applications:

Therapeutic Targets for Immunotherapy:

19. Dysregulation of Cell Cycle Pathway Genes in Lung Epithelial Cells Across Tumor Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression patterns of a comprehensive panel of cell cycle pathway genes within Lung Epithelial cells, comparing normal tissue, early-stage tumors (Tumor(early)), and advanced-stage tumors (Tumor(adv)). The goal is to identify genes with statistically significant expression differences that may indicate cell cycle dysregulation associated with lung cancer initiation and progression. The expression is represented as the "expressing cell fraction (sample)," indicating the proportion of cells within each sample that express the gene.

Visual Summary

The box plots display the distribution of expressing cell fractions for several key cell cycle genes across the three conditions. Key observations include:

Differential Expression Between Tumor Stages

Biological Interpretation

The observed expression changes in these cell cycle genes in Lung Epithelial cells provide strong evidence of disrupted cell cycle regulation in lung cancer. Lung Epithelial cells are identified as the tumor origin cell type, making these findings highly relevant to the oncogenic process.

  1. Increased Proliferative Capacity in Tumors: The consistent upregulation of genes like DBF4, E2F4, MCM7, and MAD2L2 in tumor conditions points to an enhanced proliferative state.
  1. Loss of Cell Cycle Checkpoint Control: The downregulation of GADD45B in advanced tumors is particularly concerning. GADD45B (Growth Arrest And DNA Damage Inducible Beta) is a stress-response gene involved in DNA repair, cell cycle arrest, and apoptosis [7]. Its decreased expression suggests a compromised ability of advanced tumor cells to undergo cell cycle arrest or apoptosis in response to DNA damage, thereby facilitating uncontrolled proliferation and accumulation of genetic mutations, which can lead to aneuploidy (consistent with ploidy_dec indicating Aneuploid cells).
  2. TP53 and MDM2 Dynamics: The higher expression of TP53 in early tumors compared to normal could represent an active stress response in initial stages of transformation, where p53 attempts to induce cell cycle arrest or apoptosis. However, its expression level is not significantly maintained in advanced tumors, possibly indicating selection for cells with inactivating mutations in TP53 or compensatory pathways that bypass p53 function.
  1. Progression-Related Dysregulation: The further significant upregulation of DBF4, E2F4, MCM7, and MAD2L2 in advanced tumors compared to early tumors suggests that cell cycle dysregulation becomes more pronounced as the disease progresses, likely contributing to the aggressive growth and metastatic potential characteristic of advanced lung cancer.

Clinical or Translational Implications

These findings highlight several cell cycle genes as potential diagnostic, prognostic, and therapeutic targets in lung cancer.

  1. Biomarkers for Diagnosis and Prognosis: The consistent upregulation of proliferation markers like MCM7, E2F4, DBF4, and MAD2L2 in tumor cells suggests their potential as biomarkers for detecting lung cancer, monitoring disease progression, or predicting patient outcomes. High expression of these genes could indicate more aggressive disease.
  1. Therapeutic Targets: The dysregulated cell cycle machinery represents a vulnerability that can be exploited for therapeutic intervention. Targeting key regulatory components like DBF4, E2F4, or the MCM complex could inhibit tumor cell proliferation.
  1. Understanding Tumor Heterogeneity and Evolution: The observed differences between early and advanced tumor stages provide insights into the evolutionary landscape of lung cancer. The shift in expression of genes like TP53 and the increased dysregulation of cell cycle drivers in advanced tumors could inform stage-specific therapeutic strategies. The ploidy inference data (Aneuploid vs. Diploid) in the obs['ploidy_dec'] further supports the notion of significant genomic instability resulting from these cell cycle defects.

---

References:

[1] GeneCards: DBF4. https://www.genecards.org/cgi-bin/carddisp.pl?gene=DBF4

[2] GeneCards: E2F4. https://www.genecards.org/cgi-bin/carddisp.pl?gene=E2F4

[3] GeneCards: MCM7. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MCM7

[4] PubMed Search: "MCM7 cancer prognosis lung". https://pubmed.ncbi.nlm.nih.gov/?term=MCM7+cancer+prognosis+lung

[5] GeneCards: MAD2L2. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MAD2L2

[6] PubMed Search: "YWHAQ cancer cell cycle". https://pubmed.ncbi.nlm.nih.gov/?term=YWHAQ+cancer+cell+cycle

[7] GeneCards: GADD45B. https://www.genecards.org/cgi-bin/carddisp.pl?gene=GADD45B

[8] GeneCards: MDM2. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MDM2

[9] PubMed Search: "MCM7 lung cancer biomarker". https://pubmed.ncbi.nlm.nih.gov/?term=MCM7+lung+cancer+biomarker

[10] PubMed Search: "CDC7 inhibitor cancer therapy". https://pubmed.ncbi.nlm.nih.gov/?term=CDC7+inhibitor+cancer+therapy

[11] PubMed Search: "E2F inhibitor cancer therapy". https://pubmed.ncbi.nlm.nih.gov/?term=E2F+inhibitor+cancer+therapy

20. Lung Epithelial Cell Gene Ontology (GSA) Analysis: Condition-Specific Pathway Enrichment

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis utilizes Gene Ontology (GSA) to identify biological processes and pathways significantly enriched in Lung Epithelial cells under different conditions: "Diploid", "Normal", "Tumor(adv)" (advanced tumor), and "Tumor(early)" (early tumor), each compared against "others" (all other conditions combined). The results are presented as bar plots showing the top enriched terms, ranked by their statistical significance (-log(p-val) and -log(q-val)). This helps elucidate the unique functional characteristics and shifts in biological activity of lung epithelial cells across varying physiological and pathological states.

Visual Summary

The provided bar plots illustrate condition-specific enrichment of Gene Ontology terms. Each plot displays terms on the y-axis, ranked by their -log(p-val) on the left panel and -log(q-val) on the right panel. Longer bars indicate higher statistical significance.

  1. GSA_up for Lung Epithelial cell: Diploid_vs_others: Shows enrichment predominantly in immune-related pathways, including complement and coagulation cascades, phagosome formation, antigen processing, and responses to bacterial and viral infections (e.g., *Staphylococcus aureus*, *Coronavirus*).
  2. GSA_up for Lung Epithelial cell: Normal_vs_others: Exhibits a similar immune-centric profile to diploid cells, with prominent terms like phagosome, *Human T-cell leukemia virus 1 infection*, and antigen processing. Notably, metabolic pathways such as PPAR signaling and valine/leucine/isoleucine degradation also appear.
  3. GSA_up for Lung Epithelial cell: Tumor(adv)_vs_others: Reveals a significant shift towards pathways involved in RNA processing (spliceosome, RNA transport), protein processing (ER, proteasome, ubiquitin-mediated proteolysis), and cell cycle regulation. Several terms related to neurodegeneration (e.g., *Amyotrophic lateral sclerosis*, *Huntington disease*, *Parkinson disease*) are highly enriched, suggesting cellular stress and protein homeostasis dysregulation.
  4. GSA_up for Lung Epithelial cell: Tumor(early)_vs_others: Presents a similar pattern to advanced tumors, with strong enrichment in spliceosome, ribosome, protein processing, and neurodegeneration-related pathways. Metabolic shifts like non-alcoholic fatty liver disease and thermogenesis are also noted.

Biological Interpretation

The GSA results highlight distinct functional states of Lung Epithelial cells across different conditions:

In both normal and diploid lung epithelial cells, there is a strong enrichment for pathways involved in innate immunity, such as the complement system, phagosome formation, and antigen processing and presentation. This reflects the crucial role of lung epithelial cells as a first line of defense against pathogens and environmental insults PubMed Search: Lung epithelial immune function. The presence of the PPAR signaling pathway in normal cells indicates active lipid metabolism and inflammation regulation, essential for maintaining tissue homeostasis GeneCards: PPARG. The immune-related terms suggest a constant state of preparedness and active interaction with the immune microenvironment.

A dramatic shift in pathway enrichment is observed in both early and advanced tumor lung epithelial cells. Key features include:

Clinical or Translational Implications

The distinctive pathway enrichments in tumor versus normal lung epithelial cells offer several clinical and translational insights:

21. Gene Set Enrichment Analysis (GSEA) Across Cell Types and Conditions in Lung Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. The plot displays the enrichment or depletion of 120 selected gene sets (pathways) across various cell type-condition combinations (Cases). Each Case compares a specific cell type within a given condition (e.g., 'Tumor(adv)') against all other cells of the same cell type from other conditions (_vs_others).

The color of each dot indicates the Normalized Enrichment Score (NES), where red signifies upregulation (positive NES) and blue signifies downregulation (negative NES) of the pathway in the test condition relative to the 'others' group. The size of the dot represents the statistical significance, with larger dots corresponding to more significant enrichment/depletion (higher -log(P) value).

Visual Summary

The dot plot reveals a complex landscape of pathway alterations across different cell types and disease conditions (Normal, Tumor(early), Tumor(adv)). Key visual patterns include:

Biological Interpretation

The GSEA results provide valuable insights into the biological processes driving lung tumorigenesis and shaping the tumor microenvironment:

Lung Epithelial Cell Transformation and Malignancy:

Remodeling of the Tumor Microenvironment:

Immune Cell Dysregulation and Activation:

Clinical or Translational Implications

The comprehensive GSEA across cell types provides a valuable resource for identifying potential therapeutic targets and understanding lung cancer progression:

22. Discussion

This comprehensive single-cell analysis provides a high-resolution view of lung cancer progression, revealing a complex interplay between malignant epithelial cells and their dynamic microenvironment. A central and defining feature of the tumor-origin Lung Epithelial cells is widespread genomic instability, evidenced by prominent aneuploidy in both early and advanced tumor stages (Section 11) and recurrent copy number amplifications of oncogenes such as EGFR and ERBB2 (HER2) (Section 4). This genomic dysregulation is a hallmark of malignancy and intensifies with disease progression, driving uncontrolled cell cycle activity as indicated by the upregulation of proliferation markers (e.g., MCM7, E2F4, DBF4) and the downregulation of cell cycle inhibitors (e.g., GADD45B) in tumor epithelial cells (Section 19). Furthermore, GSEA and GSA analyses confirm that tumor epithelial cells exhibit significantly enriched pathways related to RNA and protein processing, ribosome function, and cell cycle, alongside a downregulation of oxidative phosphorylation and activation of stress-response pathways (Sections 20, 21), collectively reflecting high proliferative demand and metabolic reprogramming.

The tumor microenvironment undergoes profound remodeling. We observe a significant increase in the proportion of malignant Alveolar Epithelial cells, which correlates with increasing aneuploidy (Sections 6, 11). Concurrently, the immune landscape shifts from robust surveillance in normal tissue to an immunosuppressive state in tumors. Specifically, anti-tumor NK cells are significantly reduced in both early and advanced tumor stages, with a progressive decline (Sections 7, 8). While early tumors show an initial upregulation of various T helper subsets (Tfh, Th22, Th17, Th2, Th1), the presence of immunosuppressive regulatory T cells (Treg) is significantly increased in early tumors (Section 8). The macrophage compartment demonstrates a clear shift from an M1/M2A-dominant profile in normal tissue to a progressively M2B-dominant phenotype in early and advanced tumors (Sections 9, 10), underscoring their active role in fostering a pro-tumorigenic environment.

Cell-cell interaction analysis further elucidates these pathological communication networks. Malignant (aneuploid) Lung Epithelial cells emerge as central hubs, engaging in extensive cross-talk with immune and stromal cells (Section 12). Key pro-tumorigenic interactions include intensified EGFR signaling (autocrine and paracrine, involving AREG, HBEGF, EREG, BTC) (Section 13), significantly upregulated TGF-beta signaling (especially via TGFB1-integrin_avb6_complex between macrophages and tumor cells) (Section 13), and the 'don't eat me' signal involving CD47-SIRPB1.complex, facilitating immune evasion (Section 12). Stromal cells, particularly fibroblasts, are actively reprogrammed into cancer-associated fibroblasts (CAFs), characterized by surface markers like FAP, MMP14, and PDGFRB (Section 17). These CAFs, along with endothelial cells, drive extensive extracellular matrix remodeling (COL-integrin interactions) and angiogenesis (VEGFA/PGF-NRP1/2 interactions) (Section 14).

Condition-specific surfaceome analysis further delineates these cellular phenotypes. Malignant Lung Epithelial cells lose normal markers (CLDN18, ABCA3) and gain oncogenic receptors (EGFR, ERBB2, MET) and immune evasive molecules (CD276/B7-H3) (Section 15). Tumor-associated macrophages upregulate markers like CXCR4, FOLR2, and ACVRL1 (Section 16). CD4+ T cells in tumors show increased expression of inhibitory immune checkpoints (TIGIT, CTLA4) and co-stimulatory molecules (ICOS, TNFRSF18, TNFRSF4), indicative of an activated but potentially exhausted or regulatory phenotype (Section 18). These detailed molecular signatures provide concrete evidence for the observed functional shifts in the tumor microenvironment.

Hypotheses:

  1. The observed aneuploidy and recurrent oncogene amplifications in lung epithelial cells directly drive their uncontrolled proliferation and metabolic reprogramming, facilitating tumor growth.
  2. The shift in immune cell composition (reduced NK/cytotoxic T cells, increased Treg/M2B macrophages) and altered cell-cell interactions (CD47-SIRPα, TGF-β, CXCL12-CXCR4) collectively establish an immunosuppressive and immune-evasive microenvironment that promotes lung cancer progression.
  3. Tumor-associated fibroblasts and endothelial cells, identified by their distinct surface markers and active remodeling/angiogenic pathways (e.g., FAP, MMP14, VEGFA-NRP), actively support tumor growth and metastasis.
  4. The dysregulated cell cycle genes (MCM7, E2F4, DBF4) and oncogenic surface receptors (EGFR, ERBB2, MET) in malignant lung epithelial cells represent critical therapeutic vulnerabilities that can be targeted to inhibit tumor proliferation.

Potential therapeutic targets:

  1. EGFR: Highly amplified in tumor-origin Lung Epithelial cells, significant autocrine/paracrine signaling, and prominent surface expression, driving proliferation. Evidence: CNV amplification (7p11.23, Image 5), strong AREG_EGFR, HBEGF_EGFR, EREG_EGFR, BTC_EGFR interactions (Image 17, 18), upregulated surface expression (Image 20), GSEA showing 'Pathways in cancer' enrichment (Image 29). Validation: In vitro: EGFR inhibitor sensitivity assays on primary tumor epithelial cells. In vivo: Test EGFR TKIs in PDX models with EGFR amplification. Clinical: Correlate EGFR amplification/expression with TKI response in lung cancer patients.
  2. TGF-beta signaling pathway: Markedly upregulated, highly immunosuppressive, promotes fibrosis, and involves crucial interactions between macrophages and aneuploid lung epithelial cells. Evidence: Strong TGFB1_TGFBR1, TGFB1_TGFBR2, TGFB1_integrin_avb6_complex interactions in tumor (Image 17, 18). Validation: In vitro: Use TGF-beta inhibitors in co-culture models to assess effects on immune suppression, EMT, and fibroblast activation. In vivo: Test TGF-beta inhibitors (e.g., Fresolimumab, Galunisertib) in lung cancer models, potentially in combination with immunotherapies.
  3. CD47: 'Don't eat me' signal highly active from Aneuploid Lung Epithelial cells to phagocytes, enabling immune evasion. Evidence: Strong CD47-SIRB1B.complex interactions in tumor conditions involving Aneuploid Lung Epi (Image 13, 14). Validation: In vitro: Test CD47 blocking antibodies on tumor cell lines with macrophages/NK cells to assess phagocytosis/killing. In vivo: Evaluate anti-CD47 antibodies in lung cancer models, especially in combination with checkpoint inhibitors.
  4. FAP (Fibroblast Activation Protein): Highly specific and robust surface marker for activated cancer-associated fibroblasts (CAFs) in early tumors, critical for ECM remodeling and pro-tumorigenic niche. Evidence: Strong FAP expression on Fibroblasts in early tumor samples (Image 22). Condition-specific CCI patterns highlighting ECM remodeling (COL-integrin) in tumors (Image 19). Validation: In vitro: Test FAP inhibitors or FAP-targeted ADCs on CAFs in co-culture systems to assess effects on proliferation, matrix remodeling, and tumor cell invasion. In vivo: Evaluate FAP-targeted therapies in lung cancer models to deplete or reprogram CAFs and assess tumor growth.
  5. MCM7: A key component of the minichromosome maintenance complex, essential for DNA replication, significantly upregulated in lung epithelial tumor cells, indicating uncontrolled proliferation. Evidence: Significant upregulation of MCM7 in both early and advanced tumor Lung Epithelial cells (p=0.00776, p=0.00513 vs. Normal), and further increased in advanced vs. early (p=0.0324) (Image 24). GSA/GSEA showing 'Cell cycle' and 'DNA replication' pathways enrichment (Images 20, 21). Validation: In vitro: RNAi-mediated knockdown of MCM7 in lung cancer cell lines to assess proliferation, apoptosis, and cell cycle arrest. In vivo: Test MCM7 inhibitors (if available) or genetic ablation in lung cancer models.

Follow-up validation ideas:

  1. Perform in vitro functional assays (e.g., co-culture experiments) using isolated Aneuploid Lung Epithelial cells with different immune (T cells, macrophages) and stromal cells (fibroblasts, endothelial cells) to validate specific CCI pathways (e.g., blocking CD47-SIRPα, TGF-β, or EGFR signaling) and assess effects on proliferation, migration, and immune cell function (e.g., phagocytosis, T cell killing).
  2. Test the therapeutic efficacy of inhibiting identified oncogenes (e.g., EGFR, ERBB2) or key signaling pathways (e.g., TGF-β, CXCL12-CXCR4) or targeting specific cell surface markers (e.g., FAP, CD276) in patient-derived xenograft (PDX) or genetically engineered mouse models (GEMMs) of lung cancer, both as monotherapy and in combination with chemotherapy or immunotherapy.
  3. Apply spatial analysis techniques (e.g., spatial transcriptomics or multiplexed imaging) to human lung cancer tissue sections to confirm the spatial proximity of interacting cell types and the expression patterns of specific ligand-receptor pairs and surface markers identified (e.g., co-localization of FAP+ fibroblasts with malignant epithelial cells).
  4. Validate selected diagnostic, prognostic, or predictive biomarkers (e.g., proliferation markers, immune checkpoint expression, macrophage/T cell ratios, CNV patterns) in larger retrospective or prospective patient cohorts using immunohistochemistry (IHC), flow cytometry, or advanced molecular diagnostics on tumor biopsies or liquid biopsies.
  5. Integrate single-cell RNA-seq with single-cell ATAC-seq or proteomics to understand the epigenetic and proteomic landscape underlying the observed transcriptomic shifts and target expression.

Limitations:

The single-cell RNA-seq data provides a static snapshot of cellular states, meaning dynamic processes such as cell state transitions or clonal evolution are inferred rather than directly observed. Computational inferences for CNV, cell-cell interactions, and ploidy rely on specific algorithms with inherent limitations and assumptions. The findings are specific to human lung tissue and the conditions analyzed, and their generalizability to other cancer types or patients may vary. While distinct markers and pathways are highlighted, some gene expression is shared, and functional redundancy or context-dependent roles of genes need further clarification. The absence of a gene or interaction in the 'top N' lists does not imply its complete absence or irrelevance, but rather that it was not among the most statistically significant or highly expressed under the applied filters. Furthermore, detailed resolution of cell subtypes might still reveal additional rare populations or transitional states. All identified targets and hypotheses require extensive experimental validation to confirm their functional roles and therapeutic efficacy.

23. Query List

  1. Show and save UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns.
  2. Show major cell type scores on UMAP and save the result.
  3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
  4. Select tumor-origin cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
  5. Show and save UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns.
  6. Show and save a population bar plot of minor cell types.
  7. Show and save a population bar plot of T cell subsets.
  8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  9. Show and save a population bar plot of macrophage subsets.
  10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  11. Select tumor-origin cells, show their ploidy populations as a bar plot, and save the result.
  12. Show and save cell-cell interaction patterns involving Lung Epithelial cells, Fibroblast, Macrophage, T cell, B cell, Dendritic cell, Endothelial cell, ILC, Mast cell, NK cell, Plasma cell, and Smooth muscle cell. Select at most 80 cell-cell interactions per group.
  13. Select only genes associated with immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save the result.
  14. Find cell-cell interactions involving major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60.
  15. Extract condition-specific markers for Lung Epithelial cell, show their expression as a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition.
  16. Extract condition-specific markers for Macrophage, show their expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
  17. Extract condition-specific markers for Fibroblast, show their expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
  18. Extract condition-specific markers for T cell CD4+, show their expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
  19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Lung Epithelial cell, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
  20. Show and save Gene Ontology (GSA) analysis results for Lung Epithelial cell as a bar plot.
  21. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r and n_pws_to_show to 120.
↑ Top